Jul 12, 2024, 23:07
Osimertinib could change the standard of care for EGFR-mutant NSCLC
Iván R. González, Medical Oncologist at Ángeles Puebla Hospital, shared on X:
“Osimertinib could change the standard of care for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC).
The LAURA trial showed that osimertinib improves progression-free survival (PFS) in patients with unresectable NSCLC, reducing the risk of progression or death by 84% vs. placebo.
The median PFS was 39.1 months vs. 5.6 months.
The most common adverse events were radiation pneumonitis, diarrhea, and rash.”
For Patients With EGFR-Mutated Lung Cancer, Osimertinib Trial Might Change Guidelines
Source: Iván R. González/X